Thursday, 12th November Clinical Oncology Society of Australia Annual Scientific Meeting 2020

This session will introduce the concept of geriatric oncology assessment and management, how to implement various assessment tools successfully to formally assess older patients before planning for oncological therapy and discussion on recent research outcomes and further research potential in the field of Geriatric Oncology.

Chairs: Dr Meera Agar & Dr Darshit Thaker

Speakers:
Dr Wee-Kheng Soo, Geriatric Oncologist, Eastern Health VIC
Dr Christopher Steer, Medical Oncologist, Border Medical Oncology NSW
Dr Darshit Thaker, Consultant Medical Oncologist & Palliative Medicine Physician, Royal Brisbane & Women's Hospital QLD
Dr Heather Lane, Geriatrician, Rockingham General Hospital WA
Dr Penny Mackenzie, Radiation Oncologist, St Andrew's Hospital, Toowoomba QLD, Icon Cancer Centre
Bernadette Kelly, Senior Occupational Therapist, Cancer Care Services, Redcliffe Hospital QLD
Stella Snape-Jenkins, Senior Occupational Therapist, Oncology Services, Caboolture Hospital QLD
Hermione Wheatley, Geriatric Oncology CN, NLCCS, Royal Brisbane & Women's Hospital QLD

This symposium has been donated to COSA from AstraZeneca. AstraZeneca had no influence on the symposium organisation, subject or content.

Description: Lilly kindly invites you to join our symposium to learn from Consultant Medical Oncologist Dr Mark Verrill (UK) & Clinical Nurse Specialist Karen Verrill (UK) on how they manage their complex MBC patients with poor prognostic factors, and what influences their CDK4&6 inhibitor prescribing decisions.

Chairs: Dr Rohit Joshi, Consultant Medical Oncologist, Director Cancer Research Adelaide Oncology & Haematology, Calvary Central Districts & North Adelaide Hospitals

Speakers:
Dr Mark Verrill, Consultant Medial Oncologist, Head of the Department of Medical Oncology and the deputy lead clinician for breast cancer in the North of England Cancer Network Karen Verrill, Clinical Nurse Specialist | Northern Centre for Cancer Care (NCCC) | Centre Head at Maggie's Centres
Fran Boyle, Medical Oncologist at North Sydney’s Mater Hospital, Director of the Patricia Ritchie Centre for Cancer Care and Research, Professor of Medical Oncology at the University of Sydney.

This morning symposium is sponsored by Eli Lilly

Description: Neuroendocrine neoplasms (NEN) are rare tumors that are highly heterogeneous with regards to their origin, responses to therapies and ultimately prognosis. Owing to this heterogeneity and the consequent complexity of NEN management, a mutil-disciplinary approach is advised for the effective management of Neuroendocrine neoplasms to facilitate optimal patient outcomes.

This educational symposium will review the current best practice in the management of NENs. It will consider both current therapeutic approaches in Medical Oncology and Nuclear Medicine as well as discussing how inclusion of other disciplines such as Nutrition in to a collaborative Multi-Discplinary Team can help to optimise patient outcomes.

Chair: David Chan, Medical Oncologist, Royal North Shore Hospital, NSW

Speakers:
David Chan, Medical Oncologist, Royal North Shore Hospital, NSW
Grace Kong, Nuclear Medicine Physician, Peter MacCallum Cancer Institute, Victoria, Australia
Erin Laing, Oncology Dietician, Peter MacCallum Cancer Institute, Victoria, Australia

This morning symposium is sponsored by Ipsen

• Establishing multidisciplinary cardio-oncology clinics – a global perspective  - Susan Dent
• Radiation-associated cardiovascular dysfunction: a holistic approach to clinical practice and research  - Eng-Siew Koh
• The role of imaging to facilitate early detection of cardiotoxicity - Tom Marwick
• Management of cardiotoxicity: What do the guidelines tell us? - Liza Thomas

• Herceptin cardiotoxicity  - John Younger
• The impact of breast cancer and then – what has happened to my heart?  - Carmel Gamble
• Cardiac complications in a young survivor of Metastatic Ewings Sarcoma – anthracycline cardiomyopathy, cardiac effects in pregnancy's  - William Parsonage
• You’re saying the treatment did WHAT? Communicating with young adults about toxicities - Jane Turner

• Practical considerations for treating patients with cancer in the COVID-19 pandemic - Eva Segelov
• Love in the time of cholera: Disruption of services due to COVID-19 at the leading referral center of Italy for Pancreatic Diseases  - Giovanni Marchegiani
• Achieving multidisciplinary consensus guidelines for managing intra-hepatic malignancies during COVID  - Aisling Barry
• Variations in perioperative nutrition care in Upper GI cancer: findings from the Australia wide NOURISH study  - Irene Deftereos

12:05 PM Panel Discussion

Co-Chairs: Curtis Forbes & Cassandra Dickens

• Preventing cancer: a public health nutrition and advocacy approach - Clare L Hughes
• The relationship between physical activity and survival following cancer  - Sandi Hayes
• Total control: the role of self-management and behaviour change in avoiding new or recurrent cancers  - Haryana Dhillon
• Smoking cessation for cancer patients - the COSA initiative - Bernard Stewart

12:05 PM Panel Discussion

• Tracking genomic and transcriptomic features of Oesophageal Adenocarcinoma for improving patients outcome - Marjan Naeini
• Population-based estimates of breast cancer risk for germline pathogenic variants identified by gene-panel testing: an Australian perspective - Tu Nguyen-Dumont
• Epithelial Mesenchymal Transition, Mammographic Breast Density, and Chemo-resistance in Breast Cancer - Erik (Rik) Thompson

12:51 PM Discussion

• A dosimetric study evaluating five different treatment techniques for whole breast radiotherapy - Amanda J Harding
• Reducing burden of cardiovascular disease in breast cancer patients and survivors: stakeholder consultation to inform a nurse-led model of care - Emma Kemp
• Cardiac outcomes in left-sided breast cancer patients treated with radiotherapy: a pilot study comparison of deep inspiration breath hold (DIBH) and free breathing - Harish Sharma

12:51 PM Discussion

• Fifteen-year quality of life outcomes in men with localised prostate cancer: an evidence base for the implementation of improved treatment decision-making - Carolyn G Mazariego
• Smoking Cessation in Head and Neck Cancer Patients: A Mixed Methods Study - Justin Smith
• Patient and carer perceptions of facilitators and barriers to early diagnosis and treatment of head and neck cancer in NSW: a qualitative study - Rebecca L Venchiarutti

12:51 PM Discussion

You saw how QOOL can help with ‘big data’, but now, here’s a session to demonstrate the real power for individual patients and their treating teams. By optimising data availability at the point of contact, learn about how QOOL can assist both you and your patient throughout the cancer care trajectory.

QOOL is an initiative of Cancer Alliance Queensland to support Queensland’s progress in delivering safe quality cancer care.  Significant improvements in cancer care have been achieved since the introduction of QOOL in 2009.  Data and clinical scenarios from QOOL will be explored in further detail in each of the presentations.

QOOL is a web-based, customisable system which supports cancer multidisciplinary teams by assisting meeting preparation, communication and documentation of essential clinical information such as diagnosis, cancer stage and recommended treatment plans. QOOL provides a centralised platform of patient data for multiple users, accessible anywhere, anytime. As a multisided platform QOOL connects clinicians to patient data drawn from 60 clinical and administrative systems. Imagine having real time data at your fingertips which allows you to manage patients, communicate with colleagues, conduct audits, participate in research and gain insights into your local practice.

The plenary will comprise 4 oral presentations showcasing various aspects of the QOOL platform: the first one will review QOOL in Action, next we showcase a statewide Myeloid MDT highlighting the benefits of collecting structured data and providing a real-world example of recording consumable genomics information; then we show you how to BYO (build your own) QOOL project; and finally we have Tracking your multidisciplinary meeting performance using QOOL-Dash.

The papers will be followed by a panel discussion where you can draw on the presenters’ firsthand experience of utilising a purpose built clinical cancer application to improve care for your patients locally.

1:50 PM Jeremy Long
Live QOOL MDT in action! 

1:56 PM Kirk Morris
Bridging the geographic divide for myeloid leukaemia – a statewide system accessible to everyone  

2:04 PM Benjamin Chua
Build your own QOOL Project

2:12 PM Bryan Chan
QOOL dash - Tracking my Lung cancer MDT performance

2:20 PM Panel Discussion 

• Live QOOL MDT in action! - Jeremy Long, Kirk Morris, Benjamin Chua and Bryan Chan

• Developing a structured fertility preservation program for children and adolescents with cancer; the Royal Children’s Hospital experience. - Catherine Allingham
• Variation in Colorectal Cancer MDT, treatment and survival outcomes: A population-based linked data study in South Australia (SA) - Elizabeth Buckley
• Impact of COVID-19 on Cancer Service Delivery; Results from an International Survey of Oncology Clinicians - Grace Chazan
• Systemic anticancer treatment changes at the start of the COVID-19 pandemic in a large metropolitan health service - Elizabeth Liow
• Measuring the impact of COVID-19 on cancer services using the Medicare Benefits Schedule (MBS) - Christine Biondi

3:30 PM Discussion

• Psychological impact of comprehensive genomic profiling results to advanced cancer patients - Phyllis Butow
• Cancer patient experience of uncertainty while waiting for genome sequencing results - Nicci Bartley
• Exercise in preventing falls and fractures for men with prostate cancer receiving androgen deprivation therapy: a modelled cost-utility analysis - Kim Edmunds
• Validation of a modified instrument to assess the financial impact of cancer treatment on Australian patients and families - Kate White
• Voluntary Assisted Dying (VAD) in Victoria: an audit of timings within the application process - Cameron McLaren

3:30 PM Discussion

• Implementing a nutrition care pathway in upper gastrointestinal surgery: a multi-site pilot study - Irene Deftereos
• Bridging the gap: Feasibility of embedding exercise therapy into an acute cancer treatment setting - Amy M Dennett
•   A cluster randomised controlled trial of guidelines and screening with implementation strategies versus guidelines and screening alone to improve pain in adults with cancer - Melanie R Lovell
• The future of sentinel lymph node biopsy in the management of invasive melanoma in Australia: a mixed-methods study using a determinants of practice implementation science framework - Andrea L Smith
• Implementing an ICG Lymphography clinic in a public health service: challenges and enablers to sustainability - Megan Trevethan
• What do participants using physical activity monitors think about data security?: A qualitative exploration - Jasmine Yee

3:42 PM Discussion

• A patient’s perspective on therapy induced cardiotoxicity - Lee A Hunt
• Cancer survivorship and the role of the GP/Primary care physician, with relevance to cardiooncology  - Elysia Thornton-Benko
• Setting Up CardioOncology Services: A Cardiologist's Perspective - Daniel Cehic
• Detecting and preventing early cardiovascular ageing during and following cancer treatment: The effects of exercise training  - Tom Bailey
• Why are you talking to me about my heart?  CVD risk stratification to identify high-risk patients  - Robyn A Clark

• Improving diagnostic stratification in leukaemia through genomics  - Steven Lane
• Advances in bronchoscopic diagnosis of lung cancer - David Fielding
• Getting the message across - communication skills to improve patient outcomes  - Fran Boyle
• Approaches to improving early detection of cancer in primary care  - Jon Emery
• Missed Opportunities in Recognition and Referral for Cancer Diagnosis Remain Common, Harmful and Preventable: Topic for a Moonshot? - Hardeep Singh

5:20 PM Panel Discussion 

• Telehealth in medical oncology - Sabe Sabesan
• Cancer pharmacy and telehealth - Marissa Ryan
• "This is SPaRTa!" (Specialist Palliative care Rural Telehealth Service) - Prem S Ram
• Telehealth for supportive survivorship care. - Jane Auchettl
• Telehealth and Cancer Genetic Counselling, the Queensland Experience - Camron Ebzery

5:15 PM Panel Discussion 

The introduction of immunotherapies has no doubt lead to greater efficacy outcomes for cancer patients across a broad range of tumour types. With these benefits, however, can come a range of immune related Adverse Reactions (irARs) that if not treated early and appropriately may have serious implications for the patient. To optimise management of patients on Immuno-Oncology (IO) treatments, patients need to be empowered to understand their treatment and to recognise and report adverse reactions or irARs early to their care team. It is also important that specialists involved in the management of patients experiencing an irAR are cognisant of the unique management required to ensure optimal patient outcomes. In this educational symposium we will explore:
- Best practice on empowering patients to be active in identifying and reporting any irARs
- How forming a collaborative cross-specialist network to treat irARs can help to optimise patient outcomes.

Chairs: 
Professor Kenneth O’Byrne, consultant and professor of Medical Oncology and Clinical Scientist, Princess Alexandra Hospital (PAH) and Queensland University of Technology (QUT) Translational Research Institute (TRI) Laboratories
A/Prof Alex Menzies, Medical Oncologist, Melanoma Institute Australia

Speakers: 
Dr Lavinia Spain, Peter MacCallum Cancer Centre, Medical Oncologist
Dr Megan Lyle, Cairns Private Hospital, Medical Oncologist
Dr Rob Zielinski, Orange Base Hospital, Medical Oncologist
A/Prof Victoria Atkinson, Princess Alexandra Hospital, Medical Oncologist 
Rebecca Kimberley, Princess Alexandra Hospital, Clinical Nurse Consultant Lung Cancer

This evening symposium is sponsored by Bristol Myers Squibb.